We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, Monitor and Analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under US Sunshine or EFPIA? Do you know what is on your data?
What will a journalist conclude when they access the public spend records? Or what will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insight give your visibility into your own spend that even CMS or DOJ world wish they would have.
Compliance Champions of the Highest Caliber Driving the Dialogue
The brightest minds and stakeholders of the highest caliber in life sciences compliance unite with an unmatched and meaningful and strategic content.
Founder of Whitelaw Compliance Group, LLC
President of Rockpointe
Head MSL Excellence at Merck
Associate at King & Spalding
Maite Vazquez Calo
Legal Expert on Data Privacy
Brian A Dahl
Principal at Dahl Compliance Consulting LLC
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
Like all large medical device manufacturers in the wake of the Sunshine Payments Act,
Zimmer Biomet was juggling the delicate balance between operational efficiency and
increased external reporting.
With a market that spanned 100 countries, it already consumed an extraordinary volume of data for internal compliance reports.
Helping thousands of people and companies communicate and work better.
MOHAMMAD OVAIS A KEYNOTE SPEAKER AT THE 5TH ANNUAL COMPLIANCE & TRANSPARENCY CONFERENCE
Pharmaceutical companies due to the critical nature of their business are always in need of up to date information, which can be applied immediately. The world we live in has become increasingly complex, with high proliferation of competition, complicated regulations and commercial considerations.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
While privacy laws in Europe show continuing evolution and attract views from both sides within the compliance/transparency space, another closely-related topic was under debate at the 7th Annual Global Transparency Reporting Congress in the UK. For transparency professionals, the decision to move towards pre-disclosure drew strong arguments from both sides. The Debate Not Ready For Pre-Disclosure As GDPR promises to award more privacy rights to physicians in Europe, does pre-disclosure make sense? One may argue against this, when considering the expenditure of time and funding this exercise demands. Even for drug and device companies ready to undertake the pre-disclosure exercise, accounting for the right technology, resources, and internal workflow are realistic, plausible obstacles. How would pre-disclosed data affect physician consent rates? […]
Accidental discovery. Life changing consequence. Happens all the time, doesn’t it? Penicillin wouldn’t have been discovered if Alexander Fleming hadn’t observed unusual growth in his lab equipment. For others in the life sciences industry—particularly in compliance—discoveries don’t always have happy endings. Data discoveries are best made quickly and internally. Yet, that doesn’t seem to happen often enough. In listing “Best Practices For Compliance Analytics,” at the 7th Annual Global Transparency Reporting Congress, Mohammad Ovais, CEO and founder qordata mentioned how this very basic step was overlooked by decision-makers across the pharma compliance/transparency space. For many pharmaceuticals, this happens because their compliance team defers to counterparts in technology. Should they wait for an analytics system to be up in place before […]
“If it ain’t broke, don’t fix it.” Pharmaceutical compliance serves the industry well by doing the exact opposite. In “Using Data Analysis For Business And Compliance Monitoring,” a qordata webinar I co-presented with Alice Cabrio, I described some of the proactive measures that have shifted compliance from functional support to an area of strategic centrality. Introducing Substantial Compliance at Roche Italy is one of them. Traditional Compliance, whose purpose is borne out of extrinsic reporting, is often reactive and diagnostic. Its approach is to meet expectations. Literally, to just comply. In other words, if the data in traditional compliance gives no indication of disease, there’s no need to look further. My team and I have managed to evolve things at […]